Navigation Links
Avastin Dropped Out Of Funded Drugs List

Nova Scotia province of Canada has announced that it will fund two additional cancer drugs but leave out colorectal cancer drug, Avastin.

Members looked at the economics and new evidence on Avastin and concluded it does not offer the same potential in early stages of cancer. Although Avastin costs an average of $35,000 per patient for 12 treatments over six months, British Columbia, Newfoundland and one Quebec health district are funding it.

Health Minister Chris D'Entremont says Oxaliplatin, a drug that treats colorectal cancer, and Mab Campath, a drug that treats chronic lymphocytic leukemia have been added to the list.

The decision was based on recommendations by the province's Cancer Systemic Therapy Policy Committee, which includes oncologists, pharmacists and cancer survivors.

According to the committee, Oxaliplatin can treat colorectal patients after surgery and prevent the disease from progressing. It is estimated that this use of Oxaliplatin has the potential to cure 20 people each year at a cost of $2.6 million.

The province will also pay for a drug called Mab Campath, used to treat chronic lymphocytic leukemia, at an estimated cost of $170,000 per year.




'"/>




Page: 1

Related medicine news :

1. Avastin under trial to test efficacy for pancreatic tumours!
2. Avastin, anti-Cancer Drug leads to Blindness and Other Complications
3. Warning on Avastin Updated
4. FDA Approval for Lung Cancer Treatment -Avastin Along with Chemotherapy
5. Cancer Drug Avastin Fights Brain Tumors too
6. Untreatable Eye Disease Improves With Avastin
7. 93 Year Old Widow, Suffering From Dementia Dies After the Ambulance Dropped Her at a Wrong Address
8. Cleanliness Standards Dropped In NHS Hospitals – Patient Report
9. OBC Creamy Layer May Be Dropped from Reservations in Institutions
10. Indian Born Dr. Death Claims All Charges Against Him are Dropped
11. Overdose of Paracetamol was Dropped
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/20/2017)... ... September 20, 2017 , ... ... specializing in medical device compliance and commercialization, has just released a new ... , FDA is more adamant than ever about medical device, pharmaceutical, and ...
(Date:9/20/2017)... ... September 20, 2017 , ... As part of The Garland ... a redesigned website. The new site – still located at http://www.garlandco.com ... and other industry users that Garland serves. , After an ambitious phase of ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... digital and social campaign, “Humans With Vaginas.” The goal is to ignite conversation ... of non-toxic personal care products. The brand has declared September “Humans with Vaginas” ...
(Date:9/20/2017)... ... 20, 2017 , ... Health & Safety Institute (HSI) is offering discounted pricing ... 40-Hour courses from now until November 30, 2017 to assist with the clean-up efforts ... to all businesses and government agencies – whether or not they will be directly ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the exciting story of ... life. This mouse sets out on a journey that will show that friends are ... creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has earned a bachelor’s ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/9/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... lasmiditan, an investigational, oral, first-in-class molecule for the acute ... to placebo in the Phase 3 SPARTAN study. Detailed ... of the International Headache Society (IHC) in ... demonstrate lasmiditan,s potential to reduce pain and provide freedom ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
Breaking Medicine Technology: